Back to results
US 12,235,269 B2Granted
Immunoassay for SARS-CoV-2 antibodies
AssigneePictor Limited
InventorsSandeep Kumar Vashist, Lionel Gilles Guiffo Djoko, Bhavesh Govind
Life of this patent
Estimating the term…
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the strain of coronavirus that causes coronavirus disease 2019 (COVID-19), the respiratory illness responsible for the COVID-19 pandemic. Antibodies produced from an immune response against SARS-CoV-2 are used to analyze prior exposure to the virus. The present invention provides methods for detecting antibodies in response to SARS-CoV-2 infection in a single multiplex immunoassay.
Claims21
A substrate for surface plasmon resonance, localized surface plasmon resonance or interferometry detection comprising:
- at least two capture elements specific for SARS-CoV-2 on the substrate, each capture element corresponding to and being able to bind a target analyte, and optionally
- a plurality of control elements selected from:
- a) at least one fiduciary marker,
- b) at least one negative control to monitor background signal,
- c) at least one negative control to monitor assay specificity,
- d) at least one positive colorimetric control, and/or
- e) at least one positive control to monitor assay performance and any combination thereof,
- wherein the capture elements are a SARS-CoV-2 structural protein, and
- wherein the target analyte is an anti-SARS-CoV-2 antibody.
6 more elements
Dependencies are inferred from the claim text.